Okoń A, Jurowski P, Goś R
Klinicznego Oddziału Okulistycznego 10 Wojskowego Szpitala Klinicznego z Poliklinika, SPZOZ w Bydgoszczy.
Klin Oczna. 2001;103(4-6):177-81.
To estimate the amount of the tear-film and its stability among women treated due to endocrinological or gynecological indications with hormone replacement therapy.
60 women treated with hormonal replacement therapy (HRT) were divided into 3 groups of examination: group 1 (20 women), treated with HRT after up to 1 year of menopausal symptoms, group 2 (20 women) treated with HRT between 1-5 years of menopausal symptoms, group 3 (20 women) treated with HRT after more than 5 years of menopausal symptoms. The secretion of the tear-film was measured using Schirmer I test and lisozyme test. The stability of the tear-film was measured with respect to the break-up time (BUT). The examinations were performed 3, 6, 12 months after HRT treatment. The values obtained before HRT treatment served as control.
Before HRT treatment we observed significantly decreased tear secretion and lower stability in group 2 and group 3 as compared with group 1. We noticed the negative correlation between the secretion of the tear film as compared to age of examined women. HRT made the tear secretion significantly increased in group 2 and group 3 after 6, 12 and 3, 6, 12 months of HRT treatment respectively. We assessed a significant improvement of the tear film stability with respect to BUT in group 2 and 3 in all months of HRT treatment. We found significant correlation between modified Schirmer I test and lisozyme test (p < 0.001).
The age and changes of the hormonal homeostasis have negative influence on the tear secretion, tear-film stability among peri and postmenopausal women. HRT treatment has beneficial influence on the tear film secretion and tear stabilization. Our results suggest that hormonal replacement therapy can be suitable for the treatment of the postmenopausal dry eye syndrome.
评估接受激素替代疗法治疗的内分泌或妇科疾病女性的泪膜量及其稳定性。
60例接受激素替代疗法（HRT）的女性被分为3组进行检查：第1组（20例女性），在出现绝经症状1年以内开始接受HRT治疗；第2组（20例女性），在出现绝经症状1至5年之间接受HRT治疗；第3组（20例女性），在出现绝经症状5年以上开始接受HRT治疗。使用Schirmer I试验和溶菌酶试验测量泪膜分泌情况。通过泪膜破裂时间（BUT）来测量泪膜稳定性。在HRT治疗后3、6、12个月进行检查。将HRT治疗前获得的值作为对照。
在HRT治疗前，我们观察到第2组和第3组与第1组相比，泪液分泌显著减少且稳定性较低。我们注意到泪膜分泌与受检女性年龄之间呈负相关。HRT分别在治疗6、12个月后使第2组泪液分泌显著增加，在治疗3、6、12个月后使第3组泪液分泌显著增加。我们评估了在HRT治疗的所有月份中，第2组和第3组泪膜稳定性在BUT方面有显著改善。我们发现改良Schirmer I试验和溶菌酶试验之间存在显著相关性（p < 0.001）。
年龄和激素稳态变化对围绝经期和绝经后女性的泪液分泌、泪膜稳定性有负面影响。HRT治疗对泪膜分泌和泪膜稳定有有益影响。我们的结果表明激素替代疗法可能适用于治疗绝经后干眼症综合征。
